Cost-effectiveness of nilotinib in patients with chronic myeloid leukaemia eligible to start the treatment-free remission phase in Italy.

Cost-effectiveness of nilotinib in patients with chronic myeloid leukaemia eligible to start the treatment-free remission phase in Italy.

2015 Value Health

Aiello, A. | Daniel, F. | D'Ausilio, A. | Snedecor, S.J. | Toumi, M. | Volume: 18, Issue: 7, Pages: A457,
https://www.doi.org/10.1016/j.jval.2015.09.1170